Hormone Research in Paediatrics

Original Paper

National Audit of Patient Choice in Pediatric GH Therapy

Langham S.a · Kirk J.b · on behalf of the British Society for Paediatric Endocrinology and Diabetes

Author affiliations

aDepartment of Endocrinology, Hospital for Sick Children, Great Ormond Street, London, and bDepartment of Endocrinology, Birmingham Children’s Hospital, Birmingham, UK

Keywords: AdherenceChildrenGrowth hormone therapyPatient choice

Related Articles for ""
Horm Res Paediatr 2011;75:101–105
https://doi.org/10.1159/000318784

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 05, 2010
Accepted: June 28, 2010
Published online: September 02, 2010
Issue release date: February 2011

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: https://www.karger.com/HRP

Abstract

Background: To assess free patient choice for pediatric patients commencing growth hormone (GH) therapy within the UK and Republic of Ireland. Methods: A semistructured questionnaire was sent to all members of the British Society for Paediatric Endocrinology and Diabetes. Results: Of 55 units responding, three do not commence patients on GH. The remaining 52 units included 21 from (all) historic growth centres, 13 from other tertiary centres, and 18 from district general hospitals. 46/52 units (89%) offer free patient choice, involving: demonstration of devices (n = 15), instructional DVDs (6), a combination of both (20), or other (3). Median (range) time spent choosing the GH device was 60 (25–150) min. Device demonstration involved: dialling up doses (39 units), assembling/dissembling (38), GH reconstitution (33), considering facilities provided by manufacturer (25), injecting patient (19), injecting parent (17), showing additional material (11), and cost consideration (4). Median (range) number of steps shown per unit was 5 (1–8), with correlation between numbers of manufacturers/devices and new patients commenced on GH per unit (R = 0.62 and 0.61, both p < 0.01), but not with time spent showing devices (R = 0.12 and 0.22, p > 0.05). Conclusion: Most units now offer some form of patient choice for new patients commencing GH therapy, although this involves several different methods, with larger units offering more manufacturers and more devices.

© 2010 S. Karger AG, Basel

References

  1. Kirk J, Clayton P: Specialist services and transitional care in paediatric endocrinology in the United Kingdom and Ireland. Clin Endo 2006;65:59–63.
    External Resources
  2. Wickramasuriya BPN, Casey A, Akhtar S, Zia R, Ehtisham S, et al: Factors determining patient choice in GH therapy. Hormone Res 2006;65:18–22.
    External Resources
  3. British Society for Paediatric Endocrinology and Diabetes (BSPED): Submission of evidence for the National Institute of Clinical Excellence Health Technology appraisal: the use of human growth hormone in children (review). www.bsped.org.uk/professional/position/docs/BSPED%20NICE%20submission%20on%20GH.pdf (accessed December 22, 2009).
  4. Kirk J: Developments in growth hormone delivery. Drug Deliv Ther 2010;5:43–47.
    External Resources
  5. Hunter I, de Vries C, Morris A, et al: Human growth hormone therapy: poor adherence equals poor growth. Arch Dis Child 2000;82(suppl 1):28.
  6. Kapoor RR, Burke SA, Sparrow SE, et al: Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008;93:147–148.
    External Resources
  7. Oyarzabal M, Aliaga M, Chueca M, Echarte G, Ulied A: Multicentre survey on compliance with growth hormone therapy: what can be improved? Acta Paediatr 1998;87:387–391.
    External Resources
  8. Desrosiers P, O’Brien P, Blethen S: Patient outcomes in the GHMonitor; the effect of delivery device on compliance and growth. Pediatr Endocrinol Rev 2005;2(suppl 3):327–331.
    External Resources
  9. National Institute for Health and Clinical Excellence: Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical Guidance CG76. 2009. www.nice.org.uk/nicemedia/live/11766/42971/42971.pdf (accessed April 25, 2010).
  10. Rennie TW, Bothamley GH, Engova D, Bates IP: Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007;30:728–735.
    External Resources
  11. National Institute for Health and Clinical Excellence: NICE. Human growth hormone (somatropin) for the treatment of growth failure in children. NICE Technology Appraisal guidance TA188. http://guidance.nice.org.uk/TA188/Guidance/doc/English (accessed June 30, 2010).
  12. Haverkamp F, Johansson L, Dumas H, Langham S, Tauber M, et al: Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Therap 2008;30:307–316.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 05, 2010
Accepted: June 28, 2010
Published online: September 02, 2010
Issue release date: February 2011

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: https://www.karger.com/HRP

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2011, Vol.75, No. 2

February 2011

Article

TAP Icon This Article is Part of
Recommend This
TOP